Clinical Trial Update: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib for relapsed/refractory IDH-mutated acute myeloid leukemia or myelodysplastic syndrome; results posted 2025-03-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome
• Myelodysplastic Syndrome
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-30